Tapewire

NYSE · USD

AGL

agilon health, inc.

Export transactions ↓
Tapewire entity
4698
SEC CIK
0001831097
Parsed reports
249

Last 12 months

Inside the activity.

5 purchase rows · 0 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202510
Dec 202500
Jan 202600
Feb 202600
Mar 202640
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
April 14, 2021 Filed Apr 16, 2021 21:28 UTC GrantCommon Stock 6,956 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027020 · doc4.xml · nonDerivative · entry 1

Richards Clay · CIK 0001855965 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,956

F1 · shares: Restricted stock units that vests in full on April 14, 2022, subject to continued service as a director.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:31 UTC
Shaker BenjaminChief Markets Officer
GrantOptions (Rights to Buy) · Derivative 46,262 $0.00 Strike: $23.00 $0.00
Disclosure

SEC source: 0001209191-21-027022 · doc4.xml · derivative · entry 2

Shaker Benjamin · CIK 0001855843 · Chief Markets Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,262

Underlying: Common Stock · 46,262 shares

Expires 2031-04-14

F2 · derivative.exercise_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

F2 · derivative.expiration_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:31 UTC
Shaker BenjaminChief Markets Officer
GrantCommon Stock 13,586 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027022 · doc4.xml · nonDerivative · entry 1

Shaker Benjamin · CIK 0001855843 · Chief Markets Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,586

F1 · shares: Restricted stock units that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:27 UTC
Kornitzer BenjaminChief Med. & Quality Officer
GrantOptions (Rights to Buy) · Derivative 18,504 $0.00 Strike: $23.00 $0.00
Disclosure

SEC source: 0001209191-21-027018 · doc4.xml · derivative · entry 2

Kornitzer Benjamin · CIK 0001855842 · Chief Med. & Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,504

Underlying: Common Stock · 18,504 shares

Expires 2031-04-14

F2 · derivative.exercise_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

F2 · derivative.expiration_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:27 UTC
Kornitzer BenjaminChief Med. & Quality Officer
GrantCommon Stock 5,434 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027018 · doc4.xml · nonDerivative · entry 1

Kornitzer Benjamin · CIK 0001855842 · Chief Med. & Quality Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,434

F1 · shares: Restricted stock units that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:26 UTC
Halkias TheodoreChief Business Officer
GrantOptions (Rights to Buy) · Derivative 18,504 $0.00 Strike: $23.00 $0.00
Disclosure

SEC source: 0001209191-21-027016 · doc4.xml · derivative · entry 3

Halkias Theodore · CIK 0001855972 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,504

Underlying: Common Stock · 18,504 shares

Expires 2031-04-14

F3 · derivative.exercise_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

F3 · derivative.expiration_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:26 UTC
Halkias TheodoreChief Business Officer
GrantCommon Stock 5,434 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027016 · doc4.xml · nonDerivative · entry 1

Halkias Theodore · CIK 0001855972 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,434

F1 · shares: Restricted stock units that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:25 UTC GrantOptions (Rights to Buy) · Derivative 11,843 $0.00 Strike: $23.00 $0.00
Disclosure

SEC source: 0001209191-21-027015 · doc4.xml · derivative · entry 2

Gourdine Michelle A · CIK 0001855956 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,843

Underlying: Common Stock · 11,843 shares

Expires 2031-04-14

F2 · derivative.exercise_date: Options that vest in three equal installments on each anniversary of April 14, 2021, subject to continued service as a director.

F2 · derivative.expiration_date: Options that vest in three equal installments on each anniversary of April 14, 2021, subject to continued service as a director.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:25 UTC GrantCommon Stock 6,956 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027015 · doc4.xml · nonDerivative · entry 1

Gourdine Michelle A · CIK 0001855956 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,956

F1 · shares: Restricted stock units that vests in full on April 14, 2022, subject to continued service as a director.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:24 UTC
Dombro LisaExper. & Innovation Officer
GrantOptions (Rights to Buy) · Derivative 40,710 $0.00 Strike: $23.00 $0.00
Disclosure

SEC source: 0001209191-21-027014 · doc4.xml · derivative · entry 2

Dombro Lisa · CIK 0001855954 · Exper. & Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,710

Underlying: Common Stock · 40,710 shares

Expires 2031-04-14

F2 · derivative.exercise_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

F2 · derivative.expiration_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:24 UTC
Dombro LisaExper. & Innovation Officer
GrantCommon Stock 11,956 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027014 · doc4.xml · nonDerivative · entry 1

Dombro Lisa · CIK 0001855954 · Exper. & Innovation Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,956

F1 · shares: Restricted stock units that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:24 UTC
Desai VeeralChief Strategy & Dev. Officer
GrantOptions (Rights to Buy) · Derivative 40,710 $0.00 Strike: $23.00 $0.00
Disclosure

SEC source: 0001209191-21-027013 · doc4.xml · derivative · entry 2

Desai Veeral · CIK 0001855973 · Chief Strategy & Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,710

Underlying: Common Stock · 40,710 shares

Expires 2031-04-14

F2 · derivative.exercise_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

F2 · derivative.expiration_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:24 UTC
Desai VeeralChief Strategy & Dev. Officer
GrantCommon Stock 11,956 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027013 · doc4.xml · nonDerivative · entry 1

Desai Veeral · CIK 0001855973 · Chief Strategy & Dev. Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 261,956

F1 · shares: Restricted stock units that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:23 UTC
Danieley JoanChief Administrative Officer
GrantOptions (Rights to Buy) · Derivative 18,504 $0.00 Strike: $23.00 $0.00
Disclosure

SEC source: 0001209191-21-027011 · doc4.xml · derivative · entry 2

Danieley Joan · CIK 0001856025 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,504

Underlying: Common Stock · 18,504 shares

Expires 2031-04-14

F2 · derivative.exercise_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

F2 · derivative.expiration_date: Options that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document
April 14, 2021 Filed Apr 16, 2021 21:23 UTC
Danieley JoanChief Administrative Officer
GrantCommon Stock 5,434 $0.00 $0.00
Disclosure

SEC source: 0001209191-21-027011 · doc4.xml · nonDerivative · entry 1

Danieley Joan · CIK 0001856025 · Chief Administrative Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,434

F1 · shares: Restricted stock units that vest in four equal installments on each anniversary of April 14, 2021, subject to continued employment.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.